Abcellera Biologics Stock Performance
| ABCL Stock | USD 3.90 0.47 13.70% |
The firm shows a Beta (market volatility) of 2.62, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abcellera Biologics will likely underperform. At this point, Abcellera Biologics has a negative expected return of -0.59%. Please make sure to confirm Abcellera Biologics' maximum drawdown, rate of daily change, and the relationship between the jensen alpha and kurtosis , to decide if Abcellera Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Abcellera Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in February 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 13.7 | Five Day Return 14.04 | Year To Date Return 13.7 | Ten Year Return (93.38) | All Time Return (93.38) |
1 | AbCellera Biologics Inc. A Bull Case Theory | 10/22/2025 |
2 | AbCellera Appoints Dr. Stephen Quake to its Board of Directors | 11/10/2025 |
3 | Is AbCellera Biologics Inc. stock safe for risk averse investors - 2025 Fundamental Recap AI Driven Stock Reports - newser.com | 11/21/2025 |
4 | AbCellera Biologics Inc. is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss | 11/25/2025 |
5 | Assessing AbCellera Biologics Valuation After New Facility Launch and Pipeline Progress | 11/26/2025 |
6 | Acquisition by Quake Stephen of 194932 shares of Abcellera Biologics at 3.47 subject to Rule 16b-3 | 12/01/2025 |
7 | AbCellera Biologics Inc Down 23 percent Since Q3 2025 Results | 12/05/2025 |
8 | Norges Bank Makes New 2.16 Million Investment in AbCellera Biologics Inc. ABCL | 12/11/2025 |
9 | AbCellera Biologics Upgraded at Wall Street Zen - MarketBeat | 12/26/2025 |
10 | Acquisition by Veronique Lecault of 539265 shares of Abcellera Biologics at 3.42 subject to Rule 16b-3 | 12/31/2025 |
11 | AbCellera Biologics Downgraded by Wall Street Zen to Sell | 01/05/2026 |
| Begin Period Cash Flow | 160.6 M | |
| Total Cashflows From Investing Activities | 121.4 M |
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Biologics Relative Risk vs. Return Landscape
If you would invest 591.00 in Abcellera Biologics on October 9, 2025 and sell it today you would lose (201.00) from holding Abcellera Biologics or give up 34.01% of portfolio value over 90 days. Abcellera Biologics is currently does not generate positive expected returns and assumes 4.2716% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Abcellera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Abcellera Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abcellera Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abcellera Biologics, and traders can use it to determine the average amount a Abcellera Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1378
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABCL |
Based on monthly moving average Abcellera Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abcellera Biologics by adding Abcellera Biologics to a well-diversified portfolio.
Abcellera Biologics Fundamentals Growth
Abcellera Stock prices reflect investors' perceptions of the future prospects and financial health of Abcellera Biologics, and Abcellera Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abcellera Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.1 | ||||
| Operating Margin | (8.52) % | ||||
| Current Valuation | 673.27 M | ||||
| Shares Outstanding | 299.34 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 1.06 X | ||||
| Price To Sales | 33.05 X | ||||
| Revenue | 28.83 M | ||||
| Gross Profit | (147.49 M) | ||||
| EBITDA | (204.15 M) | ||||
| Net Income | (162.86 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 65.36 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.22 X | ||||
| Cash Flow From Operations | (108.56 M) | ||||
| Earnings Per Share | (0.57) X | ||||
| Market Capitalization | 1.17 B | ||||
| Total Asset | 1.36 B | ||||
| Retained Earnings | 116.93 M | ||||
| Working Capital | 674.76 M | ||||
About Abcellera Biologics Performance
By examining Abcellera Biologics' fundamental ratios, stakeholders can obtain critical insights into Abcellera Biologics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Abcellera Biologics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 11.77 | 9.55 | |
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.28) | (0.27) | |
| Return On Assets | (0.14) | (0.13) | |
| Return On Equity | (0.18) | (0.17) |
Things to note about Abcellera Biologics performance evaluation
Checking the ongoing alerts about Abcellera Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abcellera Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abcellera Biologics generated a negative expected return over the last 90 days | |
| Abcellera Biologics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 28.83 M. Net Loss for the year was (162.86 M) with loss before overhead, payroll, taxes, and interest of (147.49 M). | |
| Abcellera Biologics currently holds about 868.21 M in cash with (108.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: AbCellera Biologics Downgraded by Wall Street Zen to Sell |
- Analyzing Abcellera Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abcellera Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Abcellera Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abcellera Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abcellera Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abcellera Biologics' stock. These opinions can provide insight into Abcellera Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.